The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.

ABSTRACT:

Rationale and objectives

The treatment of glioma with bevacizumab results in decreased enhancement, making it challenging to diagnose tumor recurrence. Therefore, the primary aim of this retrospective study was to determine if the underlying biological processes occurring within regions of recurrent glioblastoma in patients undergoing bevacizumab therapy influence morphologic and diffusion-weighted magnetic resonance (MR) imaging characteristics.

Materials and methods

In this Health Insurance Portability and Accountability Act-compliant and institutional review board-approved study, 26 patients treated with bevacizumab for high-grade glioma underwent lesion-wide apparent diffusion coefficient analysis before therapy and at the time of clinical/radiological progression, allow

SUBMITTER: Barajas RF 

PROVIDER: S-EPMC5571825 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature